We spoke to Dr Pavel Osmančik (Department of Arrhythmology, University Hospital Královské Vinohrady, Prague, Czech Republic) about the results from the PRAGUE-17 study and left atrial appendage closure, and the current strategies for preventing cardioembolic events in patients with atrial fibrillation.
Speaker’s Disclosures: Pavel Osmančik has nothing to declare in relation to this video interview.
1. What are the current strategies for preventing cardioembolic events in patients with atrial fibrillation? (0:04)
2. The PRAGUE-17 study examined the efficacy of percutaneous left atrial appendage closure compared with novel anticoagulation agents; what are your observations at this point? (0:53)
3. Which patient populations do you consider are most likely to benefit from left atrial appendage closure? (2:47)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with the Arrhythmia Alliance (A-A) at the European Society of Cardiology (ESC) Congress 2019 in Paris, France, September 2019.
Share this Video
Related Videos In Atrial Fibrillation
Faizel Osman, A-A Heart Rhythm Updates 2021: 2020 ESC AF Guidelines
We spoke to Professor Faizel Osman (Consultant Cardiologist and Electrophysiologist, University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK) who gave us an update about the recent new ESC Guidelines for Atrial Fibrillation and the upcoming Arrhythmia Alliance Heart Rhythm Updates 2021. Questions What are the most important new recommendations in the 2020 ESC atrial […]
Suneet Mittal, AF Symposium 2021: Atrial Fibrillation in the Post-COVID-19 Environment
We spoke to Dr Suneet Mittal (Director of Electrophysiology, The Valley Hospital, Ridgewood, NJ, USA) about the workflow innovations for atrial fibrillation ablation in the post-COVID-19 environment. Questions What have been the main challenges to atrial fibrillation (AF) ablation workflow during the COVID-19 pandemic? (0.14) What workflow innovations have been created and incorporated over the […]
Hugh Calkins, AF Symposium 2021: the STOP Persistent AF Clinical Trial
We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about the STOP Persistent AF Clinical Trial (NCT03012841). Questions: Could you tell us a little about the aims and design of the STOP Persistent AF clinical trial? (0.13) What were the findings of the study? (0.43) What are their implications for clinical practice? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!